Bristol-Myers Squibb stock holds above $63 as new myeloma drug wins FDA accelerated approval

Bristol-Myers Squibb (US1078421011) stock closed at $63.83 on August 14, 2026, as investors digested fresh regulatory wins in multiple myeloma and evolving earnings expectations for the coming years. Recent sector reports as of August 17, 2026 highlight accelerated FDA approvals that expand the companys oncology franchise and help frame the stocks valuation in the mid-$60s.

Share price, valuation and analyst expectations

According to a detailed quote overview from TradingKey, Bristol-Myers Squibb shares last traded at $63.83 at the close on August 14, 2026, down 1.25 percent on the day. The same overview shows a 12-month low of $42.52 and a 12-month high of $68.10, placing the latest price closer to the upper end of that trading range, which underscores how sentiment has improved compared with the lows reported earlier in the year.

Market data compiled in a sector snapshot by MarketScreener indicates that Bristol-Myers Squibb is valued at about $130 billion at a share price of $63.83, which implies that the company trades at a substantial large-cap premium within global pharmaceuticals. A separate valuation review from GuruFocus calculates an intrinsic value of $56.48 per share for BMY versus the recent market price of $63.83, suggesting that the stock is 13.0 percent above this particular fair-value estimate based on its GF Value model.

Consensus forecasts referenced in several institutional holding reports on MarketBeat point to an expected full-year 2026 earnings per share of $6.95. That compares with the companys own FY 2026 guidance range of $6.75 to $7.00 per share, indicating that analyst expectations are aligned toward the midpoint to upper half of managements range and reinforcing the narrative of moderate earnings growth.

Recent earnings performance and guidance

The most recent detailed quarterly figures in the institutional summary from MarketBeat highlight a strong prior earnings beat that still shapes perceptions of the companys profit profile. In that earlier period, Bristol-Myers Squibb reported earnings per share of $2.04, which exceeded consensus estimates of $1.60 by $0.44, and generated revenue of $12.97 billion compared with expectations of $11.74 billion, a positive gap of $1.23 billion.

Those results represented revenue growth of 5.7 percent versus the same quarter a year earlier, while earnings per share rose from $1.46 in the prior-year quarter to $2.04, a gain of $0.58 per share. The same recap notes that Bristol-Myers Squibb delivered a net margin of 18.87 percent and return on equity of 66.90 percent in that historical quarter, underlining the companys ability to convert its global drug portfolio into cash-generative profits.

Looking ahead, the company has issued full-year 2026 guidance of $6.75 to $7.00 in earnings per share, with the analyst community centered on a forecast of $6.95 per share for the same year as summarized in a MarketBeat research note. This tight range, in which the high end of guidance is only $0.25 per share above the low end, suggests that management has a reasonably clear view of near-term profitability, while the modest upside of analyst estimates versus intrinsic-value models illustrates the debate around valuation.

Consensus rating and institutional positioning

Multiple institutional-filings summaries compiled by MarketBeat emphasize that Bristol-Myers Squibb currently carries a consensus rating of Moderate Buy, with an average 12-month price target of $66.06. This target sits roughly $2.23 above the recent closing price of $63.83, signaling that the average analyst sees room for single-digit percentage upside rather than a dramatic re-rating.

The same series of reports from MarketBeat also highlight active institutional trading in BMY, with some asset managers increasing positions and others trimming exposure as they balance the stocks defensive attributes against valuation questions. An ownership analysis from TradingKey notes that as of the first quarter of 2026, 4,176 institutions collectively held 84.35 percent of Bristol-Myers Squibb shares, reinforcing the stocks status as an institutionally dominated blue chip within healthcare.

This deep institutional base, combined with a consensus Moderate Buy stance and a clustered price-target range around the mid-$60s, means that large investors are focusing on execution against guidance and the pace of new drug launches as the primary drivers of incremental returns, rather than betting on a major rerating of the valuation multiple.

FDA approvals expand multiple myeloma portfolio

Sector research summaries from OriginBrief highlight that the FDA recently granted accelerated approval to a Bristol-Myers Squibb drug identified as iberdomide for relapsed or refractory multiple myeloma, with coverage on August 14, 2026. The same report describes iberdomide as the first medicine in a novel drug class for multiple myeloma, which represents a strategic extension of the companys long-standing leadership in hematologic malignancies.

An additional healthcare innovation roundup from OriginBrief notes that a Bristol-Myers Squibb therapy branded as Zenbexus received FDA approval as the first drug in a new class of cancer medicines called CELMoDs for multiple myeloma, reported in mid-August 2026. While naming conventions differ between sources, the key takeaway is that regulators have endorsed a new generation of targeted molecules intended to improve outcomes in heavily pretreated myeloma patients.

For investors, this wave of regulatory decisions matters because multiple myeloma has historically been a significant revenue contributor for the company through earlier agents, and the extension into CELMoD and related mechanisms can help offset patent expiries and pricing pressure in older oncology products. Combined with the companys existing hematology platform, these approvals could support revenue growth beyond the 5.7 percent quarterly increase recorded in the historical earnings comparison and help justify earnings-per-share guidance in the high-$6 range for 2026.

Competitive and legal context

Within the broader oncology landscape, a newsletter from Bloomberg dated August 17, 2026 highlights that another major pharmaceutical company recently halted a cancer drug trial, intensifying investor scrutiny of late-stage oncology pipelines. That development has indirect relevance for Bristol-Myers Squibb, because setbacks at competitors can either open commercial white space in specific indications or raise questions about the risk profile of similar mechanisms across the sector.

At the same time, the valuation note from GuruFocus references a lawsuit with a potential financial impact sized at $6.7 billion, which is part of the narrative used to justify a modest overvaluation relative to the GF Value estimate. While litigation outcomes remain uncertain, the scale of the alleged exposure is material when compared with the companys quarterly revenue of $12.97 billion in the historical period and helps explain why some valuation models embed a discount to the prevailing market price.

Together, these competitive and legal factors mean that the upside from new multiple myeloma approvals coexists with headline risk around pipeline execution and legal contingencies. For long-term holders, the balance between these forces will influence whether the stock can sustainably trade above the $66.06 consensus target or converges closer to intrinsic-value estimates in the mid-$50s.

Flagship multiple myeloma therapies

Within its hematology portfolio, Bristol-Myers Squibb has built a multi-pronged approach to treating multiple myeloma that spans traditional agents and newer targeted therapies. The recent FDA accelerated approval for iberdomide, as cited in the August 17, 2026 sector summary from OriginBrief, adds a further pillar aimed at patients whose disease has relapsed or become refractory after prior lines of therapy.

In parallel, the approval highlighted for Zenbexus in the healthcare innovation roundup from OriginBrief underscores the companys ambition in CELMoD technology, which is designed to modulate the cereblon E3 ligase complex and promote targeted protein degradation in malignant cells. These agents complement existing backbone regimens and can be combined or sequenced to expand treatment options for patients.

For Bristol-Myers Squibb, success in multiple myeloma is strategically important because it can deliver meaningful incremental revenue while leveraging existing commercial infrastructure and medical expertise. If CELMoD-based therapies and other novel agents gain share in relapsed and refractory settings, they can help drive future quarterly revenue growth above the 5.7 percent pace recorded in the historical comparison and support earnings-per-share delivery within or above the indicated $6.75 to $7.00 range for 2026.

Bristol-Myers Squibb stock and current market view

As of the close on August 14, 2026, Bristol-Myers Squibb stock changed hands at $63.83 on the New York Stock Exchange according to TradingKey, with the price sitting between the 12-month low of $42.52 and the 12-month high of $68.10 reported in the same data set. Combined with an estimated market capitalization of $130 billion from the MarketScreener comparison excerpt, the latest quote reflects how investors are assigning a sizeable premium to the companys pipeline and cash flows despite legal and competitive uncertainties.

With consensus earnings expectations of $6.95 per share for 2026, the recent share price of $63.83 implies a forward price-to-earnings ratio of roughly 9.2 times, which sits modestly above the intrinsic-value estimate of $56.48 per share from the GF Value framework but still compares favorably with many faster-growing but higher-multiple peers. For shareholders, the key questions now are whether the multiple myeloma approvals and ongoing execution can sustain revenue and profit growth at or above the 5.7 percent historical rate while navigating litigation and sector competition.

Read more

More on Bristol-Myers Squibb stock

Key oncology franchise example

One of the most representative elements of Bristol-Myers Squibbs business model is its broad oncology franchise, which includes immuno-oncology, hematology, and targeted therapies aimed at solid tumors and blood cancers. The recent regulatory approvals for novel multiple myeloma agents, as detailed in the August 2026 sector summaries from OriginBrief, illustrate how the company seeks to continually refresh this portfolio with new mechanisms such as CELMoDs.

By investing in multiple modalities and indications, Bristol-Myers Squibb aims to create a diversified oncology revenue stream that can help balance the impact of upcoming patent expirations in earlier generations of drugs. For patients, this translates into a wider array of treatment choices and combinations, while for the company it provides a path to maintaining or expanding the net margin of 18.87 percent and sustaining double-digit returns on equity reported in historical periods when new therapies succeed commercially.

NYSE listing and recent price level

Bristol-Myers Squibb stock trades on the New York Stock Exchange under the ticker BMY. Based on the latest available quote snapshot from TradingKey, the shares closed at $63.83 on August 14, 2026, with a daily decline of 1.25 percent, while remaining within the 12-month range of $42.52 to $68.10. This places the current level somewhat below the consensus target of $66.06, but modestly above the intrinsic-value estimate of $56.48 discussed in valuation models, and highlights how the market is weighing strong cash generation and new drug approvals against legal and competitive overhangs.

Company facts

Company: Bristol-Myers Squibb Co.
ISIN: US1078421011
Ticker: BMY
Exchange: New York Stock Exchange
Price (as of August 14, 2026, 4:00 p.m. ET): $63.83 USD
Market cap: $130 billion (as of August 14, 2026)
Sector / Industry: Health Care / Pharmaceuticals & Biotechnology
Index membership: S&P 500